SCHEMBL425535

SCHEMBL425535

CN(C(=O)n1cnc(-c2ccc3ccccc3c2)c1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.49
CTRC Q99895 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
CA12 O43570 1/20 0.41
ACHE P22303 4/20 0.40
LIPE Q05469 4/20 0.40
BCHE P06276 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40
TUBB6 Q9BUF5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425399 0.90 RAB9A (0.43) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL427476 0.88 FAAH (0.57) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL425371 0.88 FAAH (0.60) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL426698 0.86 FAAH (0.52) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL426694 0.85 ACHE (0.49) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL425550 0.85 FAAH (0.51) FAAHSMN1; SMN2LMNATP53KDM4E
SCHEMBL426994 0.85 FAAH (0.51) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL425400 0.85 FAAH (0.54) FAAHCTRCSMN1; SMN2ACHELIPE
SCHEMBL427556 0.82 FAAH (0.49) FAAHSMN1; SMN2ACHELIPELMNA
SCHEMBL425420 0.82 FAAH (0.52) FAAHSMN1; SMN2KDM4ECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CTRC 584/4885SMN1; SMN2 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.